{"id":13740,"date":"2021-09-20T08:05:20","date_gmt":"2021-09-20T08:05:20","guid":{"rendered":"https:\/\/zeepedia.com\/?p=13740"},"modified":"2021-11-01T09:07:17","modified_gmt":"2021-11-01T09:07:17","slug":"hemlibra","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/hemlibra\/","title":{"rendered":"Hemlibra &#8211; Emicizumab uses, dose and side effects"},"content":{"rendered":"\n<p>30 mg \/ 1 ml solution for injection<br>emicizumab<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. What Hemlibra is and what it is used for<\/h2>\n\n\n\n<p><strong>What Hemlibra is<\/strong><\/p>\n\n\n\n<p>Hemlibra contains the active substance emicizumab.&nbsp;It belongs to a group of medicines called monoclonal&nbsp;antibodies.&nbsp;Monoclonal&nbsp;antibodies&nbsp;are a type of&nbsp;protein&nbsp;that recognizes and binds to a target in the body.<\/p>\n\n\n\n<p><strong>What Hemlibra is used for<\/strong><\/p>\n\n\n\n<p>Hemlibra is a medicine used to treat patients of all ages with:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>either&nbsp;hemophilia&nbsp;A which has developed inhibitory&nbsp;antibody&nbsp;to&nbsp;factor VIII<\/li><li>or severe&nbsp;haemophilia&nbsp;A that has not developed inhibitory&nbsp;antibodies&nbsp;to&nbsp;factor VIII&nbsp;(blood levels of factor VIII are less than 1%).<\/li><\/ul>\n\n\n\n<p>Hemophilia&nbsp;A is a hereditary disease caused by a deficiency of&nbsp;factor VIII, which is a necessary substance required for the blood to clot (coagulate) and stop all kinds of bleeding.<\/p>\n\n\n\n<p>The drug prevents bleeding or reduces bleeding episodes in patients with this disease.<\/p>\n\n\n\n<p>Some patients with&nbsp;hemophilia&nbsp;A may develop inhibitors of&nbsp;factor VIII&nbsp;(&nbsp;antibodies&nbsp;to&nbsp;factor VIII&nbsp;) that prevent the action of replacement&nbsp;factor VIII.<\/p>\n\n\n\n<p><strong>How Hemlibra works<\/strong><\/p>\n\n\n\n<p>Hemlibra restores the function of missing activated&nbsp;factor VIII&nbsp;which is needed for efficient&nbsp;coagulation&nbsp;(clotting) of the blood.&nbsp;The structure of Hemlibra differs from&nbsp;factor VIII&nbsp;and therefore Hemlibra is not affected by the&nbsp;factor VIII&nbsp;inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">2. What you need to know before using Hemlibra<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not use Hemlibra<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>if you are allergic to emicizumab or any of the other ingredients of this medicine (listed in section 6).&nbsp;If you are not sure, talk to your doctor, pharmacist or nurse before using Hemlibra.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and cautions<\/h2>\n\n\n\n<p><strong>Before you start using Hemlibra, it is very important to talk to your doctor about the use of medicines that have&nbsp;factor VIII&nbsp;inhibitor bypass activity, so-called &#8220;bypass preparations&#8221; (medicines that help the blood to clot but work in a different way than&nbsp;factor VIII&nbsp;)<\/strong>.&nbsp;This is because treatment with such medicines may need to be changed while you are receiving Hemlibra.&nbsp;Examples of such drugs include activated prothrombin complex concentrate (aPCC) and&nbsp;recombinant&nbsp;FVIIa (rFVIIa).&nbsp;<strong>Serious and potentially life-threatening&nbsp;adverse reactions&nbsp;may occur when aPCC is used in patients also receiving Hemlibra:<\/strong><\/p>\n\n\n\n<p><strong>Serious&nbsp;side effects&nbsp;of using aPCC during treatment with Hemlibra.<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Degradation of&nbsp;red blood cells&nbsp;(thrombotic microangiopathy)<\/strong><ul><li>This is a serious condition that can be life threatening.<\/li><li>When people have this condition, the inside of the blood vessels can be damaged and blood clots can develop in small blood vessels.&nbsp;In some cases, this can cause damage to the kidneys and other organs.<\/li><li>Be careful if you have a high risk of developing this condition (have had this condition before or have a relative who has had it), or if you are taking medicines that may increase the risk of developing this condition such as ciclosporin, quinine or tacrolimus.<\/li><li>It is important to recognize the symptoms of thrombotic microangiopathy if you develop this condition (see section 4 \u201cPossible side effects\u201d for a list of symptoms).<\/li><\/ul><\/li><\/ul>\n\n\n\n<p><strong>Stop using Hemlibra and aPCC and talk to a doctor immediately<\/strong>&nbsp;if you or your healthcare provider notice any symptoms of thrombotic microangiopathy.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Blood clots (&nbsp;thromboembolism&nbsp;)<\/strong><ul><li>In rare cases, a blood clot can form inside blood vessels and block them, which can be life-threatening.<\/li><li>It is important to recognize the symptoms of such blood clots if they develop (see section 4 \u201cPossible side effects\u201d for a list of symptoms).<\/li><\/ul><\/li><\/ul>\n\n\n\n<p><strong>Stop using Hemlibra and aPCC and talk to a doctor immediately<\/strong>&nbsp;if you or your healthcare provider notice any symptoms of blood clots in your blood vessels.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Children younger than one year<\/h2>\n\n\n\n<p>In children younger than one year, the blood system is still developing.&nbsp;If the child is younger than one year, your doctor may only prescribe Hemlibra after carefully weighing the expected benefits against the risks of using this medicine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and Hemlibra<\/h2>\n\n\n\n<p>Tell your doctor or pharmacist if you have recently taken or might take any other medicines.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Use of&nbsp;bypass&nbsp;preparations while receiving Hemlibra<ul><li><strong>Talk to your doctor before using Hemlibra and carefully follow their instructions for when&nbsp;to use&nbsp;bypass&nbsp;preparations and what&nbsp;dose&nbsp;and schedule to use.&nbsp;<\/strong>Hemlibra increases the ability of your blood to clot.&nbsp;Therefore, the&nbsp;dose of&nbsp;one of the&nbsp;bypass&nbsp;preparations required may be lower than the&nbsp;dose&nbsp;you used before starting Hemlibra.<\/li><li><strong>Use aPCC only if<\/strong>&nbsp;no other treatment options can be used.&nbsp;If aPCC is still required, talk to your doctor if you feel you need more than a total of 50 units \/ kg of aPCC.&nbsp;For more information on using aPCC while you are receiving Hemlibra, see section 2: \u201cSerious&nbsp;side effects&nbsp;of using aPCC during treatment with Hemlibra\u201d.<\/li><li>Despite limited experience with concomitant use of antifibrinolytics (drugs that cause the blood to coagulate) with aPCC or rFVIIa in patients treated with Hemlibra, you should be aware that there is a risk of thrombotic disease when antifibrinolytics are given&nbsp;intravenously&nbsp;in combination with aPCC or rFVIIa.<\/li><\/ul><\/li><\/ul>\n\n\n\n<p><strong>Laboratory tests<\/strong><\/p>\n\n\n\n<p>Tell your doctor if you use Hemlibra before taking samples to measure how well your blood is clotting.&nbsp;This is because Hemlibra in the blood can interfere with some laboratory tests, leading to incorrect results.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy and breastfeeding<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>You should use an effective method of contraception during treatment with Hemlibra and for 6 months after your last&nbsp;injection&nbsp;of Hemlibra.<\/li><li>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.&nbsp;Your doctor will consider the benefits to you of taking Hemlibra against the risks to your child.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Driving and using machines<\/h2>\n\n\n\n<p>This medicine is unlikely to affect your ability to drive or use any tools or machines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">3. How to use Hemlibra<\/h2>\n\n\n\n<p>Hemlibra is supplied in single-use vials in the form of a ready-to-use solution without first diluting.&nbsp;A doctor qualified to care for patients with&nbsp;hemophilia&nbsp;will start your treatment with Hemlibra.&nbsp;Always use this medicine exactly as your doctor has told you.&nbsp;If you are not sure, talk to your doctor.<\/p>\n\n\n\n<p><strong>Take notes<\/strong><\/p>\n\n\n\n<p>Write down the name and batch number of the medicine each time you use Hemlibra.<\/p>\n\n\n\n<p><strong>How much Hemlibra to use<\/strong><\/p>\n\n\n\n<p>Dose&nbsp;one of Hemlibra depends on your weight and your doctor will calculate the amount (in mg) and the corresponding volume of Hemlibra (in ml) to be injected, as follows:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Dosage&nbsp;one of the loading dose: Week 1 to 4:&nbsp;Dose&nbsp;one is 3 milligrams for each kilogram you weigh and is injected once a week.<\/li><li>Dosage&nbsp;of maintenance dose: From week 5 onwards:&nbsp;Dose&nbsp;one is either 1.5 milligrams for every kg you weigh, injected once a week, 3 milligrams for every kg you weigh, injected every two weeks, or 6 milligrams for every kg you weigh , injected every four weeks.<\/li><\/ul>\n\n\n\n<p>The decision to use either 1.5 mg\/kg once a week, 3 mg\/kg every other week, or 6 mg\/kg every four weeks as a maintenance dose should be made in consultation with your doctor and healthcare provider, if available.<\/p>\n\n\n\n<p>Different Hemlibra concentrations (30 mg\/ml and 150 mg\/ml)&nbsp;<strong>should not<\/strong>&nbsp;be combined in the same&nbsp;injection&nbsp;when the total volume is to be injected.<\/p>\n\n\n\n<p>The amount of Hemlibral solution given with each&nbsp;injection&nbsp;should not exceed 2 ml.<\/p>\n\n\n\n<p><strong>How Hemlibra is given<\/strong><\/p>\n\n\n\n<p><strong>If you are injecting Hemlibra yourself or if your healthcare provider is giving&nbsp;you an&nbsp;injection, you or your healthcare provider must carefully read and follow the instructions in section 7, &#8220;User instructions&#8221;.<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Hemlibra is given as an&nbsp;injection&nbsp;under the skin (&nbsp;subcutaneously&nbsp;).<\/li><li>Your doctor or nurse will show you how to inject Hemlibra.<\/li><li>Once you have been trained, you should be able to inject this medicine yourself, or with the help of your healthcare provider.<\/li><li>To insert the needle correctly under the skin, pinch a fold of loose skin at the cleansed injection site with your free hand.&nbsp;Squeezing the skin is important to ensure that you inject under the skin (into the adipose tissue) but not deeper (into a muscle).&nbsp;Injecting into a muscle can cause discomfort.<\/li><li>Prepare and&nbsp;inject&nbsp;one under clean and germ-free conditions using aseptic technique.&nbsp;You will receive more information about this from your doctor or nurse.<\/li><\/ul>\n\n\n\n<p><strong>Where to inject Hemlibra<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Your doctor will show you which areas of the body are suitable for&nbsp;injection&nbsp;of Hemlibra.<\/li><li>The recommended places to give an&nbsp;injection&nbsp;are: the front of the waist (lower abdomen), the outside of the upper arm or the front of the thighs.&nbsp;Use only the recommended injection sites.<\/li><li>For each new&nbsp;injection&nbsp;, use a different area of \u200b\u200bthe body than the one you used before.<\/li><li>Do not&nbsp;inject&nbsp;where the skin is red, bruised, tender, hard or in areas where there are birthmarks or scars.<\/li><li>When you use Hemlibra, any other medicine that is injected under the skin should be given in a different area.<\/li><\/ul>\n\n\n\n<p><strong>Use syringes and needles<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>A&nbsp;syringe&nbsp;, a transfer needle with a 5 micrometer filter and an injection needle are used to draw Hemlibral solution from the vial and inject it under the skin.<\/li><li>Syringes, transfer needles with filters and injection needles are not included in this package.&nbsp;For further information, see section 6 &#8220;What is needed when using Hemlibra and is not included in the package&#8221;.<\/li><li>Make sure you use a new injection needle for each&nbsp;injection&nbsp;and discard it after use.<\/li><li>A 1 ml&nbsp;syringe&nbsp;should be used to&nbsp;inject&nbsp;you with up to 1 ml of Hemlibral solution.<\/li><li>A 2 to 3 ml&nbsp;syringe&nbsp;should be used for&nbsp;injections&nbsp;of more than 1 ml and up to 2 ml of Hemlibral solution.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Use for children and adolescents<\/h2>\n\n\n\n<p>Hemlibra can be used in adolescents and children of all ages.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>A child can inject this medicine themselves, provided that the child&#8217;s healthcare provider and parent or caregiver agree.&nbsp;Self-injection for children under 7 years of age is not recommended.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">If you use more Hemlibra than you should&nbsp;<\/h2>\n\n\n\n<p>If you take more Hemlibra than you should, tell your doctor immediately.&nbsp;This is because you are at risk of developing&nbsp;side effects&nbsp;such as blood clots.&nbsp;Always use Hemlibra exactly as your doctor has told you and check with your doctor, pharmacist, or nurse if you are not sure.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you forget to use Hemlibra<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>If you forget to take your scheduled&nbsp;injection&nbsp;, inject the missed&nbsp;dose&nbsp;as soon as possible before the day of your next scheduled&nbsp;dose&nbsp;.&nbsp;Then continue to inject the medicine according to the schedule.&nbsp;Do not inject two&nbsp;doses&nbsp;on the same day to compensate for a missed&nbsp;dose&nbsp;.<\/li><li>If you are not sure what to do, ask your doctor, pharmacist or nurse.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">If you stop using Hemlibra<\/h2>\n\n\n\n<p>Do not stop using Hemlibra without talking to your doctor first.&nbsp;If you stop using Hemlibra, you may no longer be protected against bleeding.<\/p>\n\n\n\n<p>If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">4. Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, this medicine can cause&nbsp;side effects, although not everybody gets them.<\/p>\n\n\n\n<p><strong>Serious&nbsp;side effects&nbsp;of using aPCC during treatment with Hemlibra<\/strong><\/p>\n\n\n\n<p><strong>Stop using Hemlibra and aPCC and contact<\/strong>&nbsp;your&nbsp;<strong>doctor immediately<\/strong>&nbsp;if you or your healthcare provider notice any of the following side effects:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Degradation of&nbsp;red blood cells&nbsp;(thrombotic microangiopathy):<\/strong><ul><li>confusion, weakness, swelling of the arms and legs, yellowing of the skin or eyes, diffuse pain in the abdomen or back, nausea, vomiting or a small amount of urine &#8211; these symptoms may be signs of thrombotic microangiopathy.<\/li><\/ul><\/li><li><strong>Blood clots (&nbsp;thromboembolism&nbsp;):<\/strong><ul><li>swelling, heat, pain or&nbsp;redness&nbsp;&#8211; these symptoms may be signs of a blood clot in a vein near the skin.<\/li><li>headaches, numbness of the face, eye pain or swelling or problems with your vision &#8211; these symptoms may be signs of a blood clot in a vein behind your eye.<\/li><li>blackening of the skin &#8211; this symptom can be a sign of severe damage to the skin tissue.<\/li><\/ul><\/li><\/ul>\n\n\n\n<p><strong>Other&nbsp;side effects&nbsp;are with the use of Hemlibra<\/strong><\/p>\n\n\n\n<p><strong>Very common:<\/strong>&nbsp;may affect more than 1 user in 10<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>reaction in the area where the&nbsp;injection&nbsp;is given (&nbsp;redness&nbsp;,&nbsp;itching&nbsp;, pain)<\/li><li>headache<\/li><li>joint pain<\/li><\/ul>\n\n\n\n<p><strong>Common<\/strong>: may affect up to 1 in 10 users<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>fever<\/li><li>muscle aches<\/li><li>diarrhea<\/li><\/ul>\n\n\n\n<p><strong>Uncommon<\/strong>: may affect up to 1 in 100 people<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>degradation of&nbsp;red blood cells&nbsp;(thrombotic microangiopathy)<\/li><li>blood clot in a vein behind your eye (cavernous sinus thrombosis)<\/li><li>severe damage to the skin tissue (skin necrosis)<\/li><li>blood clot in a vein near the skin surface (superficial&nbsp;thrombophlebitis&nbsp;)<\/li><\/ul>\n\n\n\n<p><em>Reporting of side effects<\/em><\/p>\n\n\n\n<p>If you get any side effects, talk to your doctor, pharmacist, or nurse.&nbsp;This also applies to any side effects not mentioned in this information.&nbsp;You can also report side effects directly to the Medical Products Agency.&nbsp;By reporting side effects, you can help increase drug safety information.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">5. How to store Hemlibra<\/h2>\n\n\n\n<p>Keep this medicine out of the sight and reach of children.<\/p>\n\n\n\n<p>Do not use this medicine after the expiry date which is stated on the carton and vial label after \u201cEXP\u201d.&nbsp;or &#8220;EXP&#8221;.&nbsp;The expiration date is the last day of the specified month.<\/p>\n\n\n\n<p>Store in a refrigerator (2 \u00b0 C to 8 \u00b0 C).&nbsp;Do not freeze.<\/p>\n\n\n\n<p>Store in the original package.&nbsp;Sensitive to light.<\/p>\n\n\n\n<p>Unopened vials that have been removed from the refrigerator can be stored at room temperature (at a maximum of 30 \u00b0 C) for up to 7 days.&nbsp;After storage at room temperature, unopened vials can be returned to the refrigerator.&nbsp;The total storage time at room temperature should not exceed 7 days.<\/p>\n\n\n\n<p>Disposable vials that have been stored at room temperature for more than 7 days or that have been exposed to temperatures above 30 \u00b0 C should be discarded.<\/p>\n\n\n\n<p>Once Hemlibra has been transferred from the vial to the syringe, it should be used immediately.&nbsp;Do not store the syringe with the solution in the refrigerator.<\/p>\n\n\n\n<p>Before using this medicine, make sure that the solution does not contain any particles or discolorations.&nbsp;The solution should be colorless to pale yellow.&nbsp;Do not use this medicine if you notice that it is cloudy, discolored, or contains visible particles.<\/p>\n\n\n\n<p>Dispose of any unused solution appropriately.&nbsp;Medicines should not be disposed of via wastewater or household waste.&nbsp;Ask your pharmacist how to dispose of medicines no longer required.&nbsp;These measures will help to protect the environment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">6. Contents of the packaging and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Content declaration<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>The active substance is emicizumab.&nbsp;Each&nbsp;vial&nbsp;of Hemlibra contains 30 mg (1 ml at a concentration of 30 mg \/ ml) emicizumab.<\/li><li>The other ingredients are L-&nbsp;arginine&nbsp;, L-histidine, L-aspartic acid, poloxamer 188 and water for injections.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What the medicine looks like and contents of the pack<\/h2>\n\n\n\n<p>Hemlibra is a&nbsp;solution for injection.&nbsp;It has a colorless to pale yellow liquid.<\/p>\n\n\n\n<p>Each pack of Hemlibra contains 1&nbsp;glass&nbsp;vial.<\/p>\n\n\n\n<p><strong>What is needed when using Hemlibra and is not included in the package.<\/strong><\/p>\n\n\n\n<p>A&nbsp;syringe, transfer needle, and injection needle are needed to draw Hemlibral solution from the vial to the syringe and inject it under the skin (see section 7, \u201cInstructions for use\u201d).<\/p>\n\n\n\n<p><strong>Syringes<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>1 ml syringe:<\/strong>&nbsp;transparent polypropylene or polycarbonate&nbsp;<strong>syringe<\/strong>&nbsp;with Luer-lock tip, 0.01 ml graduation&nbsp;<strong>or<\/strong><\/li><li><strong>2 to 3 ml syringe:<\/strong>&nbsp;clear polypropylene or polycarbonate&nbsp;<strong>syringe<\/strong>&nbsp;with Luer-lock tip, 0.1 ml graduation.<\/li><\/ul>\n\n\n\n<p><strong>Needles<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Transfer&nbsp;<\/strong><strong>needle with filter<\/strong>&nbsp;: Stainless steel with Luer-lock connection, gauge 18 G, length 35 mm (1\u00bd \u2033), with a filter of 5 micrometers and preferably with a semi-blunt tip&nbsp;<strong>and<\/strong><\/li><li><strong>Injection needle<\/strong>&nbsp;: Stainless steel with Luer lock connection, gauge 26 G, (acceptable range: 25-27 gauge), length preferably 9 mm (3\/8 \u2033) or maximum 13 mm (\u00bd \u2033), preferably with needle safety device.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing Authorisation Holder<\/h2>\n\n\n\n<p>Roche Registration GmbH&nbsp;<\/p>\n\n\n\n<p>Emil-Barell-Strasse 1<\/p>\n\n\n\n<p>79639 Grenzach-Wyhlen&nbsp;<\/p>\n\n\n\n<p>Germany<\/p>\n\n\n\n<p><strong>Manufacturer<\/strong><\/p>\n\n\n\n<p>Roche Pharma AG<\/p>\n\n\n\n<p>Emil-Barell-Strasse 1<\/p>\n\n\n\n<p>D-79639 Grenzach-Wyhlen<\/p>\n\n\n\n<p>Germany<\/p>\n\n\n\n<p>Roche Austria GmbH<\/p>\n\n\n\n<p>Engelhorngasse 3<\/p>\n\n\n\n<p>A-1211 Vienna<\/p>\n\n\n\n<p>Austria<\/p>\n\n\n\n<p>Contact the representative of the marketing authorization holder to find out more about this medicine:<\/p>\n\n\n\n<p><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Belgium \/ Belgique \/ Belgien<\/strong>NV Roche SATel: +32 (0) 2 525 82 11<\/td><td><strong>Lithuania<\/strong>UAB \u201cRoche Lietuva\u201dTel: +370 5 2546799<\/td><\/tr><tr><td><strong>Bulgaria<\/strong>Rosh BULGARIA LOODETel: +359 2 818 44 44<\/td><td><strong>Luxembourg \/ Luxemburg<\/strong>(See \/ See Belgium \/ Belgium)<\/td><\/tr><tr><td><strong>Czech Republic<\/strong>Roche sroTel: +420 &#8211; 2 20382111<\/td><td><strong>Hungary<\/strong>Roche (Hungary) Kft.Tel: +36 &#8211; 23 446 800<\/td><\/tr><tr><td><strong>Denmark<\/strong>Roche a \/ sTel: +45 &#8211; 36 39 99 99<\/td><td><strong>Malta<\/strong>(See Ireland)<\/td><\/tr><tr><td><strong>Germany<\/strong>Roche Pharma AGTel: +49 (0) 7624 140<\/td><td><strong>The Netherlands<\/strong>Roche Nederland BVTel: +31 (0) 348 438050<\/td><\/tr><tr><td><strong>Eesti<\/strong>Roche Eesti O\u00dcTel: + 372 &#8211; 6 177 380<\/td><td><strong>Norway<\/strong>Roche Norge ASTel: +47 &#8211; 22 78 90 00<\/td><\/tr><tr><td><strong>Greece<\/strong>Roche (Hellas) AE:\u0397\u03bb: +30 210 61 66 100<\/td><td><strong>Austria<\/strong>Roche Austria GmbHTel: +43 (0) 1 27739<\/td><\/tr><tr><td><strong>Spain<\/strong>Roche Farma SATel: +34 &#8211; 91 324 81 00<\/td><td><strong>Poland<\/strong>Roche Polska Sp.z ooTel: +48 &#8211; 22 345 18 88<\/td><\/tr><tr><td><strong>France<\/strong>RocheTel: +33 (0) 1 47 61 40 00<\/td><td><strong>Portugal<\/strong>Roche Pharmac\u00eautica Chemica, LdaTel: +351 &#8211; 21 425 70 00<\/td><\/tr><tr><td><strong>Croatia<\/strong>Roche dooTel: + 385 1 47 22 333<\/td><td><strong>Romania<\/strong>Roche Rom\u00e2nia SRLTel: +40 21 206 47 01<\/td><\/tr><tr><td><strong>Ireland<\/strong>Roche Products (Ireland) Ltd.Tel: +353 (0) 1 469 0700<\/td><td><strong>Slovenia<\/strong>Roche pharmacevtska dru\u017eba dooTel: +386 &#8211; 1 360 26 00<\/td><\/tr><tr><td><strong>Iceland<\/strong>Roche a \/ sc \/ o Icepharma hfPhone: +354 540 8000<\/td><td><strong>Slovak Republic<\/strong>Roche Slovensko, sroTel: +421 &#8211; 2 52638201<\/td><\/tr><tr><td><strong>Italy<\/strong>Roche SpATel: +39 &#8211; 039 2471<\/td><td><strong>Finland \/ Finland<\/strong>Roche Oy&nbsp;Puh \/ Tel: +358 (0) 10 554 500<\/td><\/tr><tr><td><strong>K&nbsp;<\/strong><strong>\u03cd\u03c0\u03c1\u03bf\u03c2<\/strong>&nbsp;\u0393.\u0391.\u03a3\u03c4\u03b1\u03bc\u03ac\u03c4\u03b7\u03c2 &amp; \u03a3\u03b9\u03b1 \u039b\u03c4\u03b4.:\u0397\u03bb: +357 &#8211; 22 76 62 76<\/td><td><strong>Sweden<\/strong>Roche ABTel: +46 (0) 8 726 1200<\/td><\/tr><tr><td><strong>Latvia<\/strong>Roche Latvija SIATel: +371 &#8211; 6 7039831<\/td><td><strong>United Kingdom<\/strong>Roche Products Ltd.Tel: +44 (0) 1707 366000<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Hemlibra contains the active substance emicizumab. It belongs to a group of medicines called monoclonal antibodies. Monoclonal antibodies are a type of protein that recognizes and binds to a target in the body.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,12116],"tags":[13863,13869,13859,13862,13865,13868,13870,13861,13867,13860,13866],"class_list":["post-13740","post","type-post","status-publish","format-standard","hentry","category-medicines","category-i","tag-benefits-of-emicizumab","tag-benefits-of-hemlibra","tag-emicizumab","tag-emicizumab-injection","tag-hemlibra","tag-hemlibra-injection","tag-hemlibra-side-effects","tag-what-emicizumab-is-used-for","tag-what-hemlibra-is-used-for","tag-what-is-emicizumab","tag-what-is-hemlibra"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/13740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=13740"}],"version-history":[{"count":5,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/13740\/revisions"}],"predecessor-version":[{"id":15317,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/13740\/revisions\/15317"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=13740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=13740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=13740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}